Efficacy of Retreatments With Intravitreal Bevacizumab
Status:
Unknown status
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years
and for its treatment there had been performed multicentric studies with Lucentis
(Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated
efficacy of bevacizumab in several pathologies but we dont know what would be the results if
we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab
for improve or stabilize visual acuity with two or more intravitreal inyections of
bevacizumab.